Great insight into what is happening with fertility markers from Fertility and Sterility.
Biomarkers of ovarian response: current and future applications
Fertility and Sterility, 01/14/2013 Review Article
Nelson S.M. et al. – This review highlights that although biomarkers of ovarian response started in the IVF clinic, their future extends well beyond the boundaries of assisted reproduction.
•With our increasing appreciation that simply maximizing oocyte yield for all patients is no longer an appropriate stimulation strategy and that age alone cannot accurately predict ovarian response, there has been an explosion in the literature regarding the utility of biomarkers to predict and individualize treatment strategies.
• Antral follicle count (AFC) and antimüllerian hormone (AMH) have begun to dominate the clinical scene, and although frequently pitted against each other as alternatives, both may contribute and indeed be synergistic.
• Their underlying technologies are continuing to develop rapidly and overcome the standardization issues that have limited their development to date.
• In the context of in vitro fertilization (IVF), their linear relationship with oocyte yield and thereby extremes of ovarian response has led to improved pretreatment patient counseling, individualization of stimulation strategies, increased cost effectiveness, and enhanced safety.
• The automation of AMH and its introduction into the routine repertoire of clinical biochemistry has tremendous potential.
• A future where primary care physicians, endocrinologists, and oncologists can rapidly assess ovarian dysfunction and the ovarian reserve more accurately than with the current standard of follicle–stimulating hormone (FSH) is an exciting possibility.
• For women, the ability to know the duration of their own reproductive life span will be empowering and allow them to redefine the meaning of family planning.